Genmab — Marts 2016
-
Van Winkel ignites the fire by referring to the fact that January was the worst month ever for biotech. “This is a good moment to get onboard”. He subsequently continues to appraise his company Genmab that has a fabulous drug with its cancer medicine Darzalex.
The market has acknowledged Genmab as ripe for takeover for two years now. Van der Winkel is not declining (or taking away / putting away / opposing) the rumors. He, to the contrary, refers to the takeover of Pharmacyclics by Abbvie for 2 -
21B USD. Johnson and Johnson were outsmarted by this a year ago. Van de Winkel: “J&J won’t let this happen once more. They, on top of this, have 35B “stored” overseas. A takeover is becoming more and more appealing to them”.
“Not that I want to let go of Genmab” he continues. But if it comes that far, then it will be a friendly takeover. However, I expect a premium of 100% on the current share price.” -
Og det var så af de mest følsomme oplysninger i Hollandsk artikel...
-
Jeg ved ikke, om det er en DuoBody.??..https://clinicaltrials.gov/ct2/show/NCT02454270?term=JNJ-64052781&rank=1
-
Tak. Jeg er sådan set med på, at Jan har oplyst, at EM1 er startet. Jeg googlede så bare lidt, da jeg egentlig undrer mig lidt over, hvorfor de vælger kun at starte op i Syd Korea. Og ifølge CT (der ellers er opdateret for nylig) er der ingen rekrutterende klinikker endnu. Nå, men så faldt jeg bare i farten over denne anden. Tak for info.
-
-
Her er artiklen fra Holland: http://penge.borsen.dk/artikel/1/321270/topchefs_udtalelser_oeger_spekulation_om_bud_paa_genmab.html
-
Til de af jer som kan sproget.
-
Læs eventuelt chathistorikken for i dag. Der er oversættelser af centrale passager samt alskens gisninger omkring disse.
-
Klik på uret i højre hjørne, så kommer chathistorikken frem.
-
Der er desværre en del faktuelle fejl i artiklen.. og der blandes lidt æbler og bananer sammen..
-
Winkel er ikke blevet udspurgt af en journalist.. det er er i hvertfald ikke den forståelse jeg har fået.. han har tværtimod nægtet at give one-on-one interview under henvisning til at der ikke var en kommunikationsmedarbejder tilstede (Rachel)
) Protein in Subjects With Relapsed or Refractory B-cell Malignancies
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind